DEMAND FOR DIGNICAP® SYSTEM REMAINS STRONG AS 32 U.S. MEDICAL CENTERS ADD DIGNITANA’S SCALP COOLING DEVICE TO THEIR CANCER CARE SERVICES
DEMAND FOR DIGNICAP® SYSTEM REMAINS STRONG AS 32 U.S. MEDICAL CENTERS ADD DIGNITANA’S FDA-CLEARED MEDICAL SCALP COOLING DEVICE TO THEIR CANCER CARE SERVICES
Lund, Sweden—July 29, 2016—Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now, or will soon be available at 32 cancer treatment centers across the U.S. The DigniCap® system is the first and only scalp cooling device to complete rigorous FDA clinical trials in America, where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.
On the heels of this recent FDA Clearance, medical centers across the country have begun offering the DigniCap scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana is rapidly expanding its reach across America as demand for the medical device accelerates. Agreements with 32 centers have now been signed, with several early adopters ordering additional units within months of initial set up.
The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment and care regimens:
| Sioux Falls, South Dakota Beverly Hills, California Los Angeles, California |
New York, New York
Louisville, Kentucky
|
“Growth in the U.S. has been robust and consistently strong for the last seven months,” said Jan Richardsson, Chief Executive Officer of Dignitana. “We are pleased to be able to meet the growing demand for DigniCap, and excited to be working with such prestigious medical centers to provide their patients with a solution to one of the most emotionally traumatic side effects of chemotherapy.”
To date, the DigniCap system has announced unit installations at the following U.S. medical centers: Bronson Battle Creek Cancer Care Center, Charleston Hematology Oncology Associates, Chesapeake Oncology and Hematology Associates, Florida Cancer Specialists & Research Institute, Hematology Oncology Consultants, a Division of Michigan Healthcare Professionals, Menorah Medical Center, Mount Sinai Beth Israel Cancer Center, Mount Sinai Comprehensive Cancer Center, Oncology & Hematology Specialists, Orange County Blood and Cancer Care, The Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai , The C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital, The START Center for Cancer Care, The Dubin Breast Center at The Mount Sinai Hospital, Toledo Clinic Cancer Center, Stamford Health Bennett Cancer Center, UCHealth Lone Tree Health Center, UCHealth’s University of Colorado Hospital and University of Colorado Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, UT Health Science Center San Antonio’s Cancer Therapy & Research Center, Wake Forest Baptist Medical Center, and Weill Cornell Medicine and NewYork-Presbyterian.
The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.
För ytterligare information vänligen kontakta:
Jan Richardsson
VD, Dignitana AB (publ)
Telefon: 046-16 30 92
E-post: jan.richardsson@dignitana.se
Om Dignitana AB (publ)
Dignitanas, med säte i Lund, affärsidé är att utveckla, tillverka och marknadsföra den medicintekniska produkten DigniCap®. Dignitana bedriver en kontinuerlig forskning och utveckling av nya användningsområden för DigniCap®. Dignitanas aktier handlas på NASDAQ OMX First North med Erik Penser Bank som Certified Adviser. För mer information gå in på: www.dignitana.se
Om skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet DigniCap® - är ett patenterat system med syfte att eliminera eller kraftigt reducera håravfall för patienter som genomgår cytostatikabehandling. DigniCap® erbjuder skalpkylning med jämn kyla, hög effektivitet, säkerhet och acceptabel komfort.
Taggar: